FindTrial
Sign In

An investigation of the predictability of carboplatin plasma concentrations in children following dosing on the basis of surface area of renal function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN79815499
Enrollment
Unknown
Registered
2001-07-01
Start date
1993-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of brain and nervous system Cancer Brain and nervous system

Interventions

Patients receiving two courses of carboplatin are randomised to one of two groups: 1. Group A: Surface area based (course I) followed by renal function based (course II) measurement. 2. Group B: Ren

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged under 18 years 2. Receiving carboplatin on at least two occasions 3. Being treated according to listed UKCCSG protocols (NB9001, NB9301, NB8702, GC8901, CNS9204, CNS9102, WAG8702) 4. Tumour site: Neuroblastoma; Extra-cranial germ cell; Brain

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026